

Murray B Urowitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1200276/publications.pdf>

Version: 2024-02-01

209
papers

25,505
citations

22153

59
h-index

6836

155
g-index

214
all docs

214
docs citations

214
times ranked

14463
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2023, 75, 998-1006.	3.4	7
2	Medium Versus High Initial Prednisone Dose for Remission Induction in Lupus Nephritis: A Propensity Score–Matched Analysis. Arthritis Care and Research, 2022, 74, 1451-1458.	3.4	6
3	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 2022, 81, 370-378.	0.9	42
4	Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. Lupus Science and Medicine, 2022, 9, e000634.	2.7	18
5	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.9	9
6	Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. Lupus Science and Medicine, 2022, 9, e000651.	2.7	18
7	Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2022, 74, 1822-1828.	3.4	9
8	Outcomes following antimalarial withdrawal in patients with quiescent systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 2022, 55, 152046.	3.4	2
9	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care and Research, 2021, 73, 1789-1795.	3.4	13
10	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. Arthritis Care and Research, 2021, 73, 1231-1235.	3.4	22
11	Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort. Journal of Rheumatology, 2021, 48, 67-73.	2.0	28
12	Systemic glucocorticoids. , 2021, , 597-609.		0
13	Propensity Score Methods in Rare Disease: A Demonstration Using Observational Data in Systemic Lupus Erythematosus. Journal of Rheumatology, 2021, 48, 321-325.	2.0	6
14	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. Annals of the Rheumatic Diseases, 2021, 80, 1.1-2.	0.9	31
15	Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis. Rheumatology, 2021, 60, 73-80.	1.9	3
16	Acquired low immunoglobulin levels and risk of clinically relevant infection in adult patients with systemic lupus erythematosus: a cohort study. Rheumatology, 2021, 60, 1456-1464.	1.9	7
17	Factors Associated With Rapid Progression to Endstage Kidney Disease in Lupus Nephritis. Journal of Rheumatology, 2021, 48, 228-231.	2.0	6
18	New EULAR/ACR 2019 SLE Classification Criteria: defining ominousness in SLE. Annals of the Rheumatic Diseases, 2021, 80, 767-774.	0.9	20

#	ARTICLE	IF	CITATIONS
19	The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2021, 23, 29.	3.5	27
20	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.9	37
21	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , 2021, 60, 4737-4747.	1.9	14
22	Immunoglobulin levels in systemic lupus erythematosus: A narrative review. <i>Lupus</i> , 2021, 30, 867-875.	1.6	8
23	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021, 30, 096120332110142.	1.6	3
24	Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 5397-5407.	1.9	48
25	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021, 73, 2293-2302.	5.6	7
26	Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2021, 8, e000448.	2.7	18
27	Barriers to medication adherence and degree of nonadherence in a systemic lupus erythematosus (SLE) outpatient population. <i>Rheumatology International</i> , 2021, 41, 1457-1464.	3.0	13
28	Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus. <i>ACR Open Rheumatology</i> , 2021, 3, 550-557.	2.1	22
29	Identifying a Response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index. <i>Arthritis Care and Research</i> , 2021, 73, 1243-1249.	3.4	13
30	Response to: Correspondence on "New EULAR/ACR 2019 SLE classification criteria: defining ominousity in SLE" by Whittall Garcia et al. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2021-221014.	0.9	0
31	1501 "Genetics of age at systemic lupus erythematosus diagnosis. , 2021, , .		0
32	1124 "Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		0
33	1107 "Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0
34	1704 "Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
35	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. <i>Lupus Science and Medicine</i> , 2021, 8, e000590.	2.7	31
36	Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE. <i>Rheumatology</i> , 2020, 59, 90-98.	1.9	40

#	ARTICLE	IF	CITATIONS
37	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 72-81.	2.0	34
38	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2020, 72, 67-77.	5.6	39
39	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2020, 72, 1800-1808.	3.4	23
40	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis and Rheumatology, 2020, 72, 658-666.	5.6	26
41	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 2020, 106, 102340.	6.5	27
42	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Annals of the Rheumatic Diseases, 2020, 79, 356-362.	0.9	40
43	Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study. Lupus Science and Medicine, 2020, 7, e000412.	2.7	11
44	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Annals of the Rheumatic Diseases, 2020, 79, 1333-1339.	0.9	35
45	Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. , 2020, , .		0
46	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). Arthritis Care and Research, 2020, , .	3.4	9
47	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis and Rheumatology, 2020, 72, 1734-1740.	5.6	17
48	Impact of the new American College of Cardiology/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2020, 79, 612-617.	0.9	25
49	Advanced Chronic Kidney Disease in Lupus Nephritis: Is Dialysis Inevitable?. Journal of Rheumatology, 2020, 47, 1366-1373.	2.0	8
50	Atherosclerotic Vascular Events in Systemic Lupus Erythematosus: An Evolving Story. Journal of Rheumatology, 2020, 47, 66-71.	2.0	13
51	Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: A Consequence of Antimalarials?. Journal of Rheumatology, 2019, 46, 64-69.	2.0	18
52	Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	3.4	70
53	Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus. Arthritis Care and Research, 2019, 71, 822-828.	3.4	31
54	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1151-1159.	0.9	759

#	ARTICLE	IF	CITATIONS
55	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1400-1412.	5.6	1,098
56	Dr. Tselios, et al, reply. Journal of Rheumatology, 2019, 46, 1422.2-1422.	2.0	0
57	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 634-640.	0.9	51
58	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. Journal of Rheumatology, 2019, 46, 492-500.	2.0	15
59	All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971â€“2013). Annals of the Rheumatic Diseases, 2019, 78, 802-806.	0.9	80
60	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1297-1307.	5.6	25
61	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology, 2019, 58, 1259-1267.	1.9	8
62	140â€¦Effect of lupus nephritis on pregnancy outcomes in systemic lupus erythematosus: an individual participant meta-analysis. , 2019, , .		0
63	60â€¦Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset with SLE. , 2019, , .		3
64	291â€¦Assessment of the QRISK2, QRISK3, SLE cardiovascular risk equation, modified framingham and framingham risk calculators as predictors of cardiovascular disease events in systemic lupus erythematosus. , 2019, , .		0
65	THU0688â€¦ASSESSMENT OF THE QRISK2, QRISK3, SLE CARDIOVASCULAR RISK EQUATION, FRAMINGHAM AND MODIFIED FRAMINGHAM RISK CALCULATORS AS PREDICTORS OF CARDIOVASCULAR DISEASE EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
66	OP0252â€¦NEUROPATHIES IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM AN INTERNATIONAL, INCEPTION COHORT STUDY. , 2019, , .		0
67	THU0250â€¦EARLY IMPROVEMENT IN SLEDAI-2K RESPONDER INDEX-50 PREDICTS SRI-4 RESPONSE IN A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF USTEKINUMAB (UST) IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
68	FRI0195â€¦EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL (DZP) IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A RANDOMISED, PLACEBO (PBO)-CONTROLLED STUDY. , 2019, , .		5
69	10â€¦Performance of SLEDAI-2K Responder Index-50 in a Randomized Placebo-Controlled Trial with Ustekinumab (UST) in Systemic Lupus Erythematosus. , 2019, , .		0
70	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Annals of the Rheumatic Diseases, 2019, 78, 1010-1012.	0.9	12
71	Differential Diagnosis and Disease Associations. , 2019, , 598-605.		0
72	Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. Annals of the Rheumatic Diseases, 2019, 78, 372-379.	0.9	59

#	ARTICLE	IF	CITATIONS
73	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2019, 71, 281-289.	5.6	55
74	Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus: As Rare as Considered?. Journal of Rheumatology, 2019, 46, 391-396.	2.0	31
75	How can we define low disease activity in systemic lupus erythematosus?. Seminars in Arthritis and Rheumatism, 2019, 48, 1035-1040.	3.4	23
76	Self-reported indirect costs are underestimated in a canadian cohort of patients with SLE. , 2019, , .		0
77	A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index. Rheumatology, 2018, 57, 1370-1376.	1.9	31
78	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 393-396.	2.0	27
79	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology, 2018, 57, 677-687.	1.9	37
80	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care and Research, 2018, 70, 1478-1487.	3.4	55
81	Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. Rheumatology, 2018, 57, 125-133.	1.9	15
82	Rituximab for Sight-Threatening Lupus-Related Retinal Vasculitis. Journal of Clinical Rheumatology, 2018, 24, 93-94.	0.9	4
83	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2018, 70, 1294-1302.	3.4	21
84	More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 90-94.	2.0	20
85	Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
86	Recommendations for the assessment of systemic lupus erythematosus in canada. , 2018, , .		0
87	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 1426-1439.	2.0	43
88	Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada. Journal of Rheumatology, 2018, 45, 1440-1447.	2.0	12
89	Monophasic Disease Course in Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 1131-1135.	2.0	10
90	Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies. Open Access Rheumatology: Research and Reviews, 2017, Volume 9, 1-9.	1.6	28

#	ARTICLE	IF	CITATIONS
91	Disease Outcomes in Glucocorticosteroid-Naive Patients With Systemic Lupus Erythematosus. Arthritis Care and Research, 2017, 69, 252-256.	3.4	14
92	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561.	0.9	268
93	Psoriasis in systemic lupus erythematosus: a single-center experience. Clinical Rheumatology, 2017, 36, 879-884.	2.2	26
94	Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Annals of the Rheumatic Diseases, 2017, 76, 543-546.	0.9	154
95	Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease. Arthritis Research and Therapy, 2017, 19, 31.	3.5	10
96	Hospitalizations in Patients with Systemic Lupus Erythematosus in an Academic Health Science Center. Journal of Rheumatology, 2017, 44, 1173-1178.	2.0	29
97	Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics. Clinical Rheumatology, 2017, 36, 1773-1778.	2.2	9
98	Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus: A Longterm Prospective Study. Journal of Rheumatology, 2017, 44, 1841-1849.	2.0	49
99	Reply. Arthritis Care and Research, 2017, 69, 1934-1934.	3.4	0
100	Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. Annals of the Rheumatic Diseases, 2017, 76, 1837-1844.	0.9	97
101	The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort. Seminars in Arthritis and Rheumatism, 2017, 46, 791-797.	3.4	7
102	Defining Low Disease Activity in Systemic Lupus Erythematosus. Arthritis Care and Research, 2017, 69, 997-1003.	3.4	71
103	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Research and Therapy, 2017, 19, 287.	3.5	1
104	Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus. Current Rheumatology Reviews, 2017, 13, 206-218.	0.8	75
105	Systemic Glucocorticoids. , 2016, , 521-531.		3
106	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis and Rheumatology, 2016, 68, 1932-1944.	5.6	40
107	Hydroxychloroquine-Induced Cardiomyopathy in Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2016, 22, 287-288.	0.9	18
108	Systemic lupus erythematosus. Nature Reviews Disease Primers, 2016, 2, 16039.	30.5	816

#	ARTICLE	IF	CITATIONS
109	Dr. Tselios, <i>et al</i> reply. Journal of Rheumatology, 2016, 43, 1767-1767.	2.0	0
110	Does Renin-Ângiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? A Case-Â“Control Study. Arthritis Care and Research, 2016, 68, 1497-1504.	3.4	12
111	Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study. Journal of Rheumatology, 2016, 43, 552-558.	2.0	35
112	Optimal Monitoring For Coronary Heart Disease Risk in Patients with Systemic Lupus Erythematosus: A Systematic Review. Journal of Rheumatology, 2016, 43, 54-65.	2.0	67
113	Modified Framingham Risk Factor Score for Systemic Lupus Erythematosus. Journal of Rheumatology, 2016, 43, 875-879.	2.0	70
114	Dyslipidemia in systemic lupus erythematosus: just another comorbidity?. Seminars in Arthritis and Rheumatism, 2016, 45, 604-610.	3.4	79
115	The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology, 2016, 55, 252-262.	1.9	370
116	Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus. Arthritis Research and Therapy, 2015, 17, 296.	3.5	18
117	Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus. Rheumatology, 2015, 54, 449-457.	1.9	37
118	Isolated Hematuria and Sterile Pyuria May Indicate Systemic Lupus Erythematosus Activity. Journal of Rheumatology, 2015, 42, 437-440.	2.0	19
119	Interferon-Î± induces altered transitional B cell signaling and function in Systemic Lupus Erythematosus. Journal of Autoimmunity, 2015, 58, 100-110.	6.5	38
120	Costs Associated With Severe and Nonsevere Systemic Lupus Erythematosus in Canada. Arthritis Care and Research, 2015, 67, 431-436.	3.4	23
121	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2015, 67, 1837-1847.	5.6	98
122	Anti-dsDNA and Antichromatin Antibody Isotypes in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus. Journal of Rheumatology, 2015, 42, 810-816.	2.0	27
123	Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study. Lupus Science and Medicine, 2015, 2, e000104.	2.7	45
124	SLEDAI-2K Does Not Conceal Worsening in a Particular System When There Is Overall Improvement. Journal of Rheumatology, 2015, 42, 1401-1405.	2.0	7
125	Lack of Interferon and Proinflammatory Cyto/chemokines in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus. Journal of Rheumatology, 2015, 42, 2318-2326.	2.0	18
126	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2015, 74, 1530-1536.	0.9	70

#	ARTICLE	IF	CITATIONS
127	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1706-1713.	0.9	391
128	Prolonged Clinical Remission in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2014, 41, 1808-1816.	2.0	90
129	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 138-142.	0.9	115
130	Switching Treatment Between Mycophenolate Mofetil and Azathioprine in Lupus Patients: Indications and Outcomes. <i>Arthritis Care and Research</i> , 2014, 66, 1905-1909.	3.4	14
131	Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? A critical appraisal. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 521-525.	3.4	41
132	Time to Recovery from Proteinuria in Patients with Lupus Nephritis Receiving Standard Treatment. <i>Journal of Rheumatology</i> , 2014, 41, 688-697.	2.0	79
133	American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2014, 41, 875-880.	2.0	28
134	Cancer risk in systemic lupus: An updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , 2013, 42, 130-135.	6.5	249
135	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. <i>Arthritis and Rheumatism</i> , 2013, 65, 2887-2897.	6.7	84
136	Systemic lupus erythematosus: an update on current pharmacotherapy and future directions. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 723-737.	3.1	23
137	Outcome measures in systemic lupus erythematosus. <i>Indian Journal of Rheumatology</i> , 2013, 8, S46-S53.	0.4	7
138	Comparison of three anti-dsDNA assays: Performance and correlation with systemic lupus erythematosus disease activity. <i>Clinical Biochemistry</i> , 2013, 46, 317-320.	1.9	25
139	The Early Protective Effect of Hydroxychloroquine on the Risk of Cumulative Damage in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2013, 40, 831-841.	2.0	105
140	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1308-1314.	0.9	78
141	In Memoriam “ Hugh A. Smythe, 1927–2012. <i>Journal of Rheumatology</i> , 2013, 40, 343-347.	2.0	1
142	Recommendations for Frequency of Visits to Monitor Systemic Lupus Erythematosus in Asymptomatic Patients: Data from an Observational Cohort Study. <i>Journal of Rheumatology</i> , 2013, 40, 630-633.	2.0	21
143	Clinical Measures, Metrics, and Indices. , 2013, , 563-581.		5
144	Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients. <i>Rheumatology</i> , 2012, 51, 528-534.	1.9	22

#	ARTICLE	IF	CITATIONS
145	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1502-1509.	0.9	143
146	High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 3052-3053.	6.7	14
147	Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. <i>Arthritis Care and Research</i> , 2012, 64, 511-518.	3.4	75
148	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
149	Mycophenolate Mofetil for Induction Treatment of Lupus Nephritis: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2011, 38, 69-78.	2.0	102
150	Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. <i>Kidney International</i> , 2011, 79, 914-920.	5.2	60
151	Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. <i>Arthritis Research and Therapy</i> , 2011, 13, R156.	3.5	71
152	Peripheral Neuropathy in Patients with Systemic Lupus Erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 203-211.	3.4	126
153	Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2011, 63, 1517-1520.	3.4	26
154	Optimal Frequency of Visits for Patients with Systemic Lupus Erythematosus to Measure Disease Activity Over Time. <i>Journal of Rheumatology</i> , 2011, 38, 60-63.	2.0	16
155	Development and Initial Validation of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50. <i>Journal of Rheumatology</i> , 2011, 38, 275-284.	2.0	72
156	The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010, 62, 863-868.	6.7	245
157	Prolonged Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Frequency and Outcome. <i>Journal of Rheumatology</i> , 2010, 37, 1822-1827.	2.0	114
158	Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2010, 12, R125.	3.5	24
159	The 1000 Canadian Faces of Lupus: Determinants of Disease Outcome in a Large Multiethnic Cohort. <i>Journal of Rheumatology</i> , 2009, 36, 1200-1208.	2.0	111
160	Myocardial Perfusion Imaging in Assessing Risk of Coronary Events in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 288-294.	2.0	36
161	Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 61, 1152-1158.	6.7	117
162	Epidemiology of atherosclerosis in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2009, 11, 248-254.	4.7	34

#	ARTICLE	IF	CITATIONS
163	Risk Factors for Development of Coronary Artery Disease in Women with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 2454-2461.	2.0	66
164	The SLICC inception cohort for atherosclerosis. <i>Current Rheumatology Reports</i> , 2008, 10, 281-285.	4.7	9
165	Changing Patterns in Mortality and Disease Outcomes for Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2008, 35, 2152-2158.	2.0	274
166	Should all patients with systemic lupus erythematosus receive cardioprotection with statins?. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 536-537.	3.2	8
167	Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. <i>Journal of Rheumatology</i> , 2007, 34, 70-5.	2.0	97
168	Summarizing disease features over time: II. Variability measures of SLEDAI-2K. <i>Journal of Rheumatology</i> , 2007, 34, 336-40.	2.0	24
169	Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide. <i>Journal of Rheumatology</i> , 2007, 34, 1491-6.	2.0	13
170	Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 54, 2211-2219.	6.7	25
171	Ethnic variation in disease patterns and health outcomes in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2006, 33, 1990-5.	2.0	46
172	Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. <i>Journal of Rheumatology</i> , 2006, 33, 1785-8.	2.0	36
173	The effect of menopause on disease activity in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2006, 33, 2192-8.	2.0	41
174	Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005, 53, 609-612.	6.7	75
175	Contributions of Observational Cohort Studies in Systemic Lupus Erythematosus: The University of Toronto Lupus Clinic Experience. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 211-221.	1.9	54
176	Premature Atherosclerosis in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 329-354.	1.9	82
177	Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. <i>Journal of Rheumatology</i> , 2005, 32, 824-7.	2.0	103
178	Prolonged remission in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2005, 32, 1467-72.	2.0	87
179	Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. <i>Arthritis and Rheumatism</i> , 2003, 48, 3159-3167.	6.7	327
180	Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. II. Predictive factors for perfusion abnormalities. <i>Journal of Rheumatology</i> , 2003, 30, 288-91.	2.0	30

#	ARTICLE	IF	CITATIONS
181	Accrual of organ damage over time in patients with systemic lupus erythematosus. Journal of Rheumatology, 2003, 30, 1955-9.	2.0	218
182	Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. Journal of Rheumatology, 2003, 30, 1977-82.	2.0	115
183	Systemic lupus erythematosus disease activity index 2000. Journal of Rheumatology, 2002, 29, 288-91.	2.0	1,911
184	Role of specialty care in the management of patients with systemic lupus erythematosus. Journal of Rheumatology, 2002, 29, 1207-10.	2.0	13
185	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. Arthritis and Rheumatism, 2000, 13, 406-408.	6.7	56
186	Atherosclerosis and systemic lupus erythematosus. Current Rheumatology Reports, 2000, 2, 19-23.	4.7	34
187	PREMATURE ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS. Rheumatic Disease Clinics of North America, 2000, 26, 257-278.	1.9	154
188	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. Arthritis and Rheumatism, 2000, 13, 406-408.	6.7	3
189	The SLICC/ACR damage index: progress report and experience in the field. Lupus, 1999, 8, 632-637.	1.6	73
190	The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with Systemic Lupus Erythematosus. Arthritis and Rheumatism, 1997, 40, 809-813.	6.7	586
191	The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis and Rheumatism, 1996, 39, 363-369.	6.7	2,042
192	Malignancy in systemic lupus erythematosus. Arthritis and Rheumatism, 1996, 39, 1050-1054.	6.7	204
193	Kidney biopsy in systemic lupus erythematosus. Arthritis and Rheumatism, 1994, 37, 559-567.	6.7	62
194	Derivation of the sledai. A disease activity index for lupus patients. Arthritis and Rheumatism, 1992, 35, 630-640.	6.7	4,086
195	Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. Arthritis and Rheumatism, 1992, 35, 849-856.	6.7	107
196	Accelerated nodulosis during azathioprine therapy. Arthritis and Rheumatism, 1991, 34, 123-124.	6.7	28
197	Kidney Biopsy in Systemic Lupus Erythematosus. II. Survival Analyses According to Biopsy Results. Arthritis and Rheumatism, 1991, 34, 1268-1273.	6.7	72
198	Pregnancy Outcome Following First Trimester Exposure to Chloroquine. American Journal of Perinatology, 1991, 8, 174-178.	1.4	104

#	ARTICLE	IF	CITATIONS
199	Kidney Biopsy in SLE. I. A Clinical-Morphologic Evaluation. QJM - Monthly Journal of the Association of Physicians, 1989, , .	0.5	13
200	Lupus retinopathy. Arthritis and Rheumatism, 1988, 31, 1105-1110.	6.7	203
201	Systemic Lupus Erythematosus and Diffuse Soft Tissue Calcifications. International Journal of Dermatology, 1983, 22, 416-418.	1.0	12
202	67Gallium lung scans in progressive systemic sclerosis. Arthritis and Rheumatism, 1983, 26, 969-974.	6.7	28
203	The significance of thrombocytopenia in systemic lupus erythematosus. Arthritis and Rheumatism, 1983, 26, 1181-1186.	6.7	60
204	Serologically active clinically quiescent systemic lupus erythematosus. American Journal of Medicine, 1979, 66, 210-215.	1.5	151
205	The bimodal mortality pattern of systemic lupus erythematosus. American Journal of Medicine, 1976, 60, 221-225.	1.5	911
206	Mixed leukocyte reaction in rheumatoid arthritis. Arthritis and Rheumatism, 1976, 19, 532-538.	6.7	11
207	THE CLINICAL SIGNIFICANCE OF IMMUNE COMPLEXES IN RHEUMATOID DISEASE. Annals of the New York Academy of Sciences, 1975, 256, 338-341.	3.8	7
208	Asymptomatic spondylodiscitis an unusual feature of ankylosing spondylitis. Arthritis and Rheumatism, 1974, 17, 487-493.	6.7	30
209	Studies into the occurrence of soluble antigen-antibody complexes in disease. Arthritis and Rheumatism, 1973, 16, 225-230.	6.7	11